Instrumentation Laboratory Successfully Completes Transition To Direct Business Model In Japan

BEDFORD, Mass., Feb. 4, 2014 /PRNewswire/ -- Instrumentation Laboratory (IL) today announced that they have successfully completed their transition to direct sales, service, support and marketing for their Hemostasis product line in Japan. A multi-faceted team of sales and technical sales representatives, field service engineers and respective managers has been deployed throughout the country, supporting end-user clinical laboratory customers. This complements the Company's Critical Care product line, which has leveraged a direct business model in Japan since 2004. Additionally, IL now has a complete direct distribution operation for their primary in vitro diagnostics product lines, Hemostasis and Critical Care, in all major markets around the world.   

(Logo: http://photos.prnewswire.com/prnh/20140204/NE58020LOGO)

"For the past ten years, we have been successfully selling and supporting our Critical Care product line directly in Japan. Transitioning to a direct model for our Hemostasis product line is a natural evolution and one we have the experience and know-how to effectively execute," said Ramon Benet, CEO at IL. "Being closer to our Hemostasis customers in Japan allows us to expedite innovation to their labs and to relay their experiences and incorporate their feedback into our product improvement and development process. They will have the benefit of support from IL headquarters, the hub of our scientific expertise and innovation. It is a very positive step for both IL and our customers in Japan." 

IL's Hemostasis products include the highly successful HemosIL^® line of reagents, ACL TOP^® Family of Hemostasis Testing Systems, ACL ELITE^®/ELITE PRO analyzers and other ACL^® systems. IL's Critical Care product line includes the innovative GEM® Premier 4000 with Intelligent Quality Management (iQM^®) system, the GEM Premier 3500 with iQM system, and GEMweb Plus^® Custom Connectivity.

Instrumentation Laboratory Successfully Completes Transition to Direct Business Model in Japan

The Company's Exclusive Distribution Agreement for Hemostasis Products with Mitsubishi Chemical Medience Corporation (MCM) ended amicably on December 31, 2013, after nearly 15 years. "We wish to acknowledge and thank MCM for their years of successful partnership with IL," said Juan Rodighiero, Country Manager at IL Japan. "They forged strong relationships with customers and laid the groundwork for the expansion of our Hemostasis products in Japan.  We appreciate their professionalism, dedication and effort which assured a smooth transition for our customers."   

Today, IL is the number one manufacturer of instruments and reagents for the Hemostasis market worldwide.  Since the introduction of the first fully automated Hemostasis analyzer, the ACL 810 in 1985, IL has continuously introduced innovative instruments and reagents to hospital and specialty labs, culminating in the release of the ACL TOP Family of Hemostasis Testing Systems. This line of fully automated analyzers is the leading Hemostasis product line in the world.   

In Critical Care diagnostics, IL has introduced innovation to the market for over fifty years, from the first direct-reading pH/blood gas analyzer; the invention of CO-Oximetry; the first information management system for blood gas; to the first standardized Critical Care testing platform for all hospital locations. Sales of IL's flagship GEM Premier 4000 analyzer continue to grow throughout the world spurred by iQM, the first and only automated, active total quality management system. In addition, GEMweb Plus 200 Custom Connectivity software offers lab managers complete control of their analyzers from any PC or GEM Premier system, operator certification and advanced regulatory management. The Company has strong, established relationships with key scientific and industry leaders in Hemostasis, and has always been the source of technical, scientific and field service expertise.  

Instrumentation Laboratory (www.ilus.com), founded in 1959, is a worldwide developer, manufacturer and distributor of in vitro diagnostic instruments, related reagents and controls for use primarily in hospitals and independent clinical laboratories. The company's product lines include critical care systems, hemostasis systems and information management systems. IL's GEM^® product offerings, part of the critical care line, include the GEM Premier™ 4000 analyzer with Intelligent Quality Management (iQM^®), GEM Premier 3500, GEMweb^® Plus Custom Connectivity, and the GEM PCL Plus, a portable coagulation analyzer.  IL's hemostasis portfolio includes the ACL TOP^® Family of Hemostasis Testing Systems, fully automated, high-productivity analyzers, including the ACL TOP 700, ACL TOP 700 LAS, ACL TOP 500 CTS and the new ACL TOP 300 CTS.  IL also offers the ACL AcuStar^®, ACL ELITE^® and ELITE PRO, other hemostasis analyzers and the HemosIL^® line of assays.  IL is based in Bedford, Massachusetts.

The Instrumentation Laboratory logo, GEM, iQM, HemosIL, ACL TOP, ACL ELITE, ACL AcuStar and Premier are trademarks of Instrumentation Laboratory Company and/or one of its subsidiaries or parent companies, and may be registered in the United States Patent and Trademark Office and in other jurisdictions.  All other product names, company names, marks, logos, and symbols are trademarks of their respective owners.
                                                                                

SOURCE Instrumentation Laboratory